Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JPS6410519B2 - - Google Patents
[go: Go Back, main page]

JPS6410519B2 - - Google Patents

Info

Publication number
JPS6410519B2
JPS6410519B2 JP55077436A JP7743680A JPS6410519B2 JP S6410519 B2 JPS6410519 B2 JP S6410519B2 JP 55077436 A JP55077436 A JP 55077436A JP 7743680 A JP7743680 A JP 7743680A JP S6410519 B2 JPS6410519 B2 JP S6410519B2
Authority
JP
Japan
Prior art keywords
substance
minutes
melanin
molecular weight
squid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP55077436A
Other languages
Japanese (ja)
Other versions
JPS574998A (en
Inventor
Shigemi Kondo
Mikio Satake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissui Corp
Original Assignee
Nippon Suisan Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Suisan Kaisha Ltd filed Critical Nippon Suisan Kaisha Ltd
Priority to JP7743680A priority Critical patent/JPS574998A/en
Publication of JPS574998A publication Critical patent/JPS574998A/en
Priority to JP63192365A priority patent/JPS6463523A/en
Publication of JPS6410519B2 publication Critical patent/JPS6410519B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は新規なメラニン系物質の製造法、更に
詳細にはイカ又はタコのスミから得た胃液分泌抑
制作用ならびに抗炎症作用を有するメラニン系物
質の製造法に関する。 従来、動物臓器から種々の有用な医薬を抽出す
ることが行われており、現在実用に供されている
ものもある。また一方、イカ及びタコは食用に供
されているが、この際生ずる多量のスミはその廃
棄に大きな問題をかかえている。 本発明者は、イカ及びタコのスミの黒色はメラ
ニン系の物質に由来するのではないか、そしても
しそうであるとするとこれには何らかの生理活性
があるのではないかと予測し、このスミの成分及
び生理活性について研究を行つた。 そして、イカ又はタコのスミをホモジナイズ
し、これを布等で過し、この液を透析して
得た内液についてその生理活性を調べたところ、
これが優れた胃液分泌抑制作用ならびに抗炎症作
用を有することを見出し、本発明を完成した。 すなわち、本発明はイカ又はタコのスミをホモ
ジナイズし、これから粗大固形分を除去した溶液
を透析処理することを特徴とする、次の物性を示
す蛋白質及び糖を含むメラニン系物質の製造法を
提供するものである。 形状:黒色無晶形の粉末 溶解性:水にやや難溶、エタノール、酢酸エ
チル、クロロホルム、ベンゼン、ジメチルホル
ムアミド、ジメチルスルホキシドに不溶 融点:300℃以上 元素分析値:C47〜50%、H3〜4%、O38〜
41%、N8〜9%、灰分0.06〜0.08% 分子量:約25000の物質と16万以上の物質と
の混合物(セフアデツクスG−100のゲル過) 紫外部吸収スペクトル:第2図 安定性 121℃、30分で失活、 N−塩酸と100℃、30分で安定、 N−苛性ソーダと100℃、30分で安定。 従来抗炎症剤として使用される薬物においては
胃腸障害に関する副作用をともなうものが多かつ
た。しかるに本発明は抗炎症作用を有するととも
に、積極的に胃腸障害をも抑制する生理活性物質
を見出したところに特徴がある。 本発明は、例えば次のようにして実施される。 先ず、イカ又はタコのスミに苛性ソーダ、苛性
カリ等のアルカリ剤を加えてPHを6〜12に調整
し、ホモジナイザー等によつて充分にホモジナイ
ズする。次いでこれを布等による過、あるい
は遠心分離等によつて固形分を除去する。溶液を
セルロースチユーブに入れ、水又は生理食塩水に
対して透析し、その内液を凍結乾燥すればメラニ
ン系物質が得られる。 このようにして得られる本発明のメラニン系物
質は次の如き物性及び生理活性を有する。 (1) 物理化学的性状 形状 黒色無晶形の粉末 溶解性 水にやや難溶、エタノール、酢酸エチル、
クロロホルム、ベンゼン、ジメチルホルムア
ミド、ジメチルスルホキシド不溶 融点 300℃以上 元素分析値 C:47〜50%、H:3〜4%、O:38〜41
%、N:8〜9%、灰分:0.06〜0.08% 分子量 セフアデツクスG−100のゲル過から、
分子量約25000の物質と16万以上の物質との
混合物である(第1図) 紫外部吸収スペクトル 第2図のとおり アミノ酸組成(透析内液50ml中)
The present invention relates to a novel method for producing a melanin-based substance, and more particularly to a method for producing a melanin-based substance obtained from squid or octopus ink that has gastric juice secretion suppressing and anti-inflammatory effects. Conventionally, various useful medicines have been extracted from animal organs, and some are currently in practical use. On the other hand, squid and octopus are eaten, but the large amount of ink produced during this process poses a major problem in their disposal. The present inventor predicted that the black color of squid and octopus ink may be derived from melanin-based substances, and if so, it may have some physiological activity. We conducted research on the ingredients and physiological activities. Then, we homogenized squid or octopus ink, passed it through a cloth, etc., and dialyzed this solution.We investigated the physiological activity of the internal fluid obtained.
The present invention was completed based on the discovery that this compound has excellent gastric juice secretion suppressing and anti-inflammatory effects. That is, the present invention provides a method for producing a melanin-based substance containing protein and sugar exhibiting the following physical properties, which is characterized by homogenizing squid or octopus ink and dialysis of a solution from which coarse solids have been removed. It is something to do. Shape: Black amorphous powder Solubility: Slightly soluble in water, insoluble in ethanol, ethyl acetate, chloroform, benzene, dimethylformamide, dimethyl sulfoxide Melting point: 300℃ or higher Elemental analysis: C47-50%, H3-4% , O38~
41%, N8-9%, ash 0.06-0.08% Molecular weight: A mixture of a substance with a molecular weight of approximately 25,000 and a substance with a molecular weight of 160,000 or more (Sephadex G-100 gel filtration) Ultraviolet absorption spectrum: Figure 2 Stability 121℃, Inactivated in 30 minutes, stable with N-hydrochloric acid at 100℃ for 30 minutes, stabilized with N-caustic soda at 100℃ for 30 minutes. Many of the drugs conventionally used as anti-inflammatory agents were associated with side effects related to gastrointestinal disorders. However, the present invention is characterized by the discovery of a physiologically active substance that not only has an anti-inflammatory effect but also actively suppresses gastrointestinal disorders. The present invention can be carried out, for example, as follows. First, an alkaline agent such as caustic soda or caustic potash is added to squid or octopus ink to adjust the pH to 6 to 12, and the mixture is sufficiently homogenized using a homogenizer or the like. Next, the solid content is removed by passing it through a cloth or by centrifugation. Melanin-based substances can be obtained by placing the solution in a cellulose tube, dialyzing it against water or physiological saline, and freeze-drying the internal solution. The melanin-based substance of the present invention thus obtained has the following physical properties and physiological activities. (1) Physicochemical properties Shape Black amorphous powder Solubility Slightly soluble in water, ethanol, ethyl acetate,
Insoluble in chloroform, benzene, dimethylformamide, dimethyl sulfoxide Melting point 300℃ or higher Elemental analysis values C: 47-50%, H: 3-4%, O: 38-41
%, N: 8-9%, Ash content: 0.06-0.08% Molecular weight From gel filtration of Sephadex G-100,
It is a mixture of a substance with a molecular weight of approximately 25,000 and a substance with a molecular weight of over 160,000 (Fig. 1) Ultraviolet absorption spectrum As shown in Fig. 2 Amino acid composition (in 50 ml of dialysis fluid)

【表】 糖 1.16%(フエノール硫酸法) 安定性 121℃、30分で失活 N−塩酸と100℃、30分で安定 N−苛性ソーダと100℃、30分で安定 以上の物性から、本発明のメラニン系物質は
蛋白質及び糖を含むメラニン系物質であること
が確認された。 (2) 急性毒性(LD50) 6週令のdd−N系マウス(体重:雄20〜27
g、雌20〜26g) 腹腔内投与 1g/Kg以上 経口投与 5g/Kg以上 (3) 生理活性 胃液分泌抑制作用 胃液分泌抑制効果の測定はShayの幽門結
紮法〔Gastroenterology、43(1945)〕に
よつて行つた。 イ 腹腔内投与 体重200〜250gのウイスター系雄性ラツ
トを24時間絶食後、エーテル麻酔下に開腹
し、幽門部を結紮した。結紮後直ちに、実
施例1(被検物A)または実施例2(被検物
B)によつて得られたメラニン系物質の生
理食塩水溶解液を腹腔内に投与した。投与
から4時間後に胃を摘出し、胃液量、総酸
度およびペプシン活性を測定した。総酸度
はフエノールフタレインを指示薬として、
0.05N−NaOHで滴定し、塩酸として
μEq/100g体重であらわした。ペプシン
活性は胃液のカゼイン水解能によつて測定
した。活性はカゼインの分解によつて遊離
するチロシンを280nmの吸光度で測定し、
チロシン量mg/100g体重に換算してあら
わした。また対照群として生理食塩水を投
与して、同様に胃液量、総酸度、ペプシン
活性を測定した。 その結果は第2表のとおりである。
[Table] Sugar 1.16% (phenol sulfuric acid method) Stability Deactivated at 121℃ for 30 minutes Stable with N-hydrochloric acid at 100℃ for 30 minutes Stable with N-caustic soda at 100℃ for 30 minutes Based on the above physical properties, the present invention The melanin-based substance was confirmed to be a melanin-based substance containing protein and sugar. (2) Acute toxicity (LD 50 ) 6-week-old dd-N mice (body weight: male 20-27
g, female 20-26 g) Intraperitoneal administration 1 g/Kg or more Oral administration 5 g/Kg or more (3) Physiological activity Gastric juice secretion suppressive effect The gastric juice secretion suppressive effect was measured using Shay's pylorus ligation method [Gastroenterology 5 , 43 (1945)] I went there by B. Intraperitoneal administration After fasting male Wistar rats weighing 200 to 250 g for 24 hours, the abdomen was opened under ether anesthesia, and the pylorus was ligated. Immediately after the ligation, a physiological saline solution of the melanin substance obtained in Example 1 (Test A) or Example 2 (Test B) was administered intraperitoneally. Four hours after administration, the stomachs were removed, and gastric juice volume, total acidity, and pepsin activity were measured. Total acidity is determined by using phenolphthalein as an indicator.
It was titrated with 0.05N-NaOH and expressed as hydrochloric acid in μEq/100g body weight. Pepsin activity was measured by the casein hydrolysis ability of gastric juice. The activity was determined by measuring the absorbance of tyrosine released by the decomposition of casein at 280 nm.
It was expressed in terms of tyrosine amount mg/100g body weight. Physiological saline was also administered as a control group, and gastric juice volume, total acidity, and pepsin activity were measured in the same manner. The results are shown in Table 2.

【表】 ロ 十二指腸内投与 十二指腸内投与における胃液分泌抑制作
用の検定は、腹腔内投与と同様の手順でお
こなつた。被検液は実施例1で得られたメ
ラニン系物質を生理食塩水に溶かし、幽門
結紮後直ちに1/4注射針を通して直接十二
指腸内に投与した。 その結果は第3表のとおりである。
[Table] b. Intraduodenal administration The inhibitory effect on gastric juice secretion during intraduodenal administration was tested using the same procedure as for intraperitoneal administration. The test solution was prepared by dissolving the melanin substance obtained in Example 1 in physiological saline, and directly administering it into the duodenum through a 1/4 injection needle immediately after pyloric ligation. The results are shown in Table 3.

【表】 抗潰瘍作用 抗潰瘍作用の検定は幽門結紮潰瘍の方法で
おこなつた。 体重200〜250gのウイスター系雄性ラツト
を48時間絶食後、胃液分泌作用の検定と同様
にして幽門部を結紮し、結紮から18時間後に
胃を摘出した。これを大彎側より切開して、
前胃部に発生する潰瘍性変化をAdamiらの
方法〔Arch.int.Pharmacodyn.、147、113
(1964)〕によつて潰瘍指数に変換した。被検
物としては、実施例1で得たものを生理食塩
水に溶かしたものを、結紮直後及び結紮から
8時間後の2回投与した。 その結果は第4表のとおりである。
[Table] Anti-ulcer effect The anti-ulcer effect was tested using the pyloric ligation ulcer method. After fasting male Wistar rats weighing 200 to 250 g for 48 hours, the pylorus was ligated in the same manner as in the assay for gastric juice secretion, and the stomach was removed 18 hours after the ligation. This is incised from the greater curvature side,
Ulcerative changes that occur in the forestomach were evaluated using the method of Adami et al. [Arch.int.Pharmacodyn., 147, 113]
(1964)] to an ulcer index. As a test substance, the substance obtained in Example 1 dissolved in physiological saline was administered twice, immediately after ligation and 8 hours after ligation. The results are shown in Table 4.

【表】 以上の実験から明らかな如く、本発明のメ
ラニン系物質は5mg/Kgの腹腔内投与及び50
mg/Kgの十二指腸内投与で有意に胃液分泌を
抑制し、また25mg/Kg、2回の腹腔内投与で
抗潰瘍作用を示す。 抗炎症作用 (イ) ラツト足蹠ラカゲニン浮腫抑制試験Van
Arman〔J.Pharmacol.Exp.Ther.、150
328(1965)〕およびWinter〔Proc.Soc.Exp.
Biol.Med.、111、544(1962)〕の方法に従
い行つた。すなわち、検体として実施例1
で得られたメラニン系物質を生理食塩水に
溶かし、これをカラゲニン注射30分前に腹
腔内に投与した。カラゲニンは1.5%生理
食塩水溶液として、各足蹠に0.1mlづつ投
与した。ラツトはウイスター系雄性、体重
130〜150gのものを用い、カラゲニン注射
直後の足容積に対する浮腫率を、経時的に
求めた。この時対照群として、生理食塩水
を腹腔内に投与し、上記の方法で足蹠浮腫
をつくり、その浮腫率を経時的に求めた。 その結果は第5表の通りである。
[Table] As is clear from the above experiments, the melanin-based substance of the present invention was administered intraperitoneally at a dose of 5 mg/Kg and
Intraduodenal administration of mg/Kg significantly suppresses gastric juice secretion, and two intraperitoneal administrations of 25 mg/Kg exhibits anti-ulcer effects. Anti-inflammatory effect (a) Rat footpad lacagenin edema suppression test Van
Arman [J.Pharmacol.Exp.Ther., 150 ,
328 (1965)] and Winter [Proc.Soc.Exp.
Biol. Med., 111 , 544 (1962)]. That is, Example 1 as a specimen
The melanin-based substance obtained was dissolved in physiological saline, and this was administered intraperitoneally 30 minutes before carrageenan injection. Carrageenin was administered as a 1.5% physiological saline solution in an amount of 0.1 ml to each footpad. Rats are Wistar males, weight
Using a sample of 130 to 150 g, the edema rate relative to the paw volume immediately after carrageenin injection was determined over time. At this time, as a control group, physiological saline was administered intraperitoneally, footpad edema was created by the above method, and the edema rate was determined over time. The results are shown in Table 5.

【表】 第5表から明らかなように、検体投与群
の浮腫率は、対照群に比べ有意に小さく、
カラゲニンによる浮腫を抑制した。また検
体投与群においては、5mg/Kg投与群の浮
腫率は1mg/Kg投与群の浮腫率より小さ
く、用量依存性が認められた。 (ロ) 刺激性に関する検討 一般に抗炎症作用を検討する場合、被検
物質が刺激性を有する時には、見かけ上浮
腫率を抑制する。そこでイカスミより得ら
れたメラニン系物質の刺激性について検討
した。 Squirmingに対する影響 ddY系雄性マウス(体重20〜22g)の
腹腔内に、実施例1で得たメラニン系物
質の生理食塩水溶液を投与し、投与から
10分後より10分間のSquirming回数を測
定した。また陽性対照として、0.7%酢
酸溶液をマウス腹腔内に投与し、同様に
Squirming回数を測定した。 その結果は第6表のとおりである。
[Table] As is clear from Table 5, the edema rate in the sample administration group was significantly lower than that in the control group.
Suppressed edema caused by carrageenan. In addition, in the sample administration group, the edema rate in the 5 mg/Kg administration group was lower than the edema rate in the 1 mg/Kg administration group, and dose dependence was observed. (b) Examination of irritation When examining anti-inflammatory effects, when the test substance is irritating, the apparent edema rate is suppressed. Therefore, we investigated the irritating properties of melanin-based substances obtained from squid ink. Effect on squirming The physiological saline solution of the melanin-based substance obtained in Example 1 was intraperitoneally administered to ddY male mice (body weight 20-22 g).
After 10 minutes, the number of squirmings for 10 minutes was measured. As a positive control, 0.7% acetic acid solution was intraperitoneally administered to mice, and the same procedure was performed.
The number of squirming was measured. The results are shown in Table 6.

【表】 第6表から明らかなように、イカスミ
より得られたメラニン系物質投与群の
Squirming回数は生理食塩水投与群と差
はなく、刺激性は認められなかつた。 血管透過性に対する作用 Whittleら〔Brit.J.Pharmacol.、22
246(1964)〕の方法に従い、ddY系雄性
マウス(体重20〜22g)に、4%−トリ
パンブルー0.1mlを尾静脈より投与し、
投与から10分後に検体を腹腔内に投与し
た。さらに20分後エーテル麻酔下に開腹
し、腹腔を5mlの水で洗い出した。洗液
中に滲出したトリパンブルーを590nm
の吸光度により求め、検体の血管透過性
に対する作用を測定した。 その結果は第7表のとおりである。
[Table] As is clear from Table 6, in the group administered with melanin-based substances obtained from squid ink,
There was no difference in the number of squirmings compared to the physiological saline administration group, and no irritation was observed. Effect on vascular permeability Whittle et al. [Brit.J.Pharmacol., 22 ,
246 (1964)], 0.1 ml of 4% trypan blue was administered via the tail vein to ddY male mice (body weight 20-22 g).
The specimen was administered intraperitoneally 10 minutes after administration. After another 20 minutes, the abdomen was opened under ether anesthesia, and the abdominal cavity was washed out with 5 ml of water. Trypan blue exuded into the washing solution was detected at 590nm.
The effect on vascular permeability of the specimen was measured. The results are shown in Table 7.

【表】 第7表からあきらかなように、検体投
与群におけるトリパンブルーの滲出量
は、生理食塩水投与群と差はなく、血管
透過性亢進作用は認められなかつた。 以上の結果イカスミより得られたメラ
ニン系物質には刺激性作用はなく、この
ことからカラゲニン浮腫抑制作用は本物
質の抗炎症作用にもとずくものであるこ
とが確認された。 次に実施例を挙げて説明する。 実施例 1 ムラサキイカ(Ommastrephes bartrami
Lesueur)のスミブクロ80個(243g)の内容物
を生理食塩水350mlで洗いだした。これに4N−苛
性ソーダ水溶液を加えてPH8に調整し、グライン
ダーミラーでホモジナイズし、これを二重ガーゼ
で過して液300mlを得た。液をセルロース
チユーブに入れ、水に対して72時間透析を行な
い、透析内液を凍結乾燥して、メラニン系物質
26.4gを得た。 実施例 2 マダコ(Octopus vulgaris Cuvier)のスミブ
クロ5個(2.5g)の内容物を生理食塩水14mlで
洗い出した。これに4N−苛性ソーダ水溶液を加
えてPH9とし、ガラス製ポツター型ホモジナイザ
ーでホモジナイズし、二重ガーゼで過して液
8mlを得た。液を実施例1と同様にして透析
し、凍結乾燥してメラニン系物質0.7gを得た。
[Table] As is clear from Table 7, the exudation amount of trypan blue in the sample administration group was not different from that in the physiological saline administration group, and no vascular permeability enhancing effect was observed. As a result of the above, the melanin substance obtained from squid ink has no irritating effect, and this confirms that the carrageenan edema suppressing effect is based on the anti-inflammatory effect of this substance. Next, an example will be given and explained. Example 1 Purple squid (Ommastrephes bartrami)
The contents of 80 pieces (243 g) of Sumibukuro (Lesueur) were washed out with 350 ml of physiological saline. The pH was adjusted to 8 by adding 4N aqueous sodium hydroxide solution, homogenized with a grinder mirror, and filtered through double gauze to obtain 300 ml of liquid. The solution was placed in a cellulose tube, dialyzed against water for 72 hours, and the dialyzed solution was freeze-dried to remove melanin-based substances.
26.4g was obtained. Example 2 The contents of 5 pieces (2.5 g) of Octopus vulgaris Cuvier were washed out with 14 ml of physiological saline. A 4N aqueous sodium hydroxide solution was added to the mixture to adjust the pH to 9, the mixture was homogenized using a glass potter type homogenizer, and filtered through double gauze to obtain 8 ml of a solution. The solution was dialyzed in the same manner as in Example 1 and freeze-dried to obtain 0.7 g of melanin-based substance.

【図面の簡単な説明】[Brief explanation of drawings]

第1図は本発明メラニン系物質のセフアデツク
スG−100によるゲル過の溶出パターンを、第
2図は同物質の紫外部吸収スペクトルを示す。
Figure 1 shows the elution pattern of the melanin-based substance of the present invention when gelled through Cephadex G-100, and Figure 2 shows the ultraviolet absorption spectrum of the same substance.

Claims (1)

【特許請求の範囲】 1 イカ又はタコのスミをホモジナイズし、これ
から粗大固形分を除去した溶液を透析処理するこ
とを特徴とする、次の物性を示す蛋白質及び糖を
含むメラニン系物質の製造法。 形状:黒色無晶形の粉末 溶解性:水にやや難溶、エタノール、酢酸エ
チル、クロロホルム、ベンゼン、ジメチルホル
ムアミド、ジメチルスルホキシドに不溶 融点:300℃以上 元素分析値:C47〜50%、H3〜4%、O38〜
41%、N8〜9%、灰分0.06〜0.08% 分子量:約25000の物質と16万以上の物質と
の混合物(セフアデツクスG−100のゲル過) 紫外部吸収スペクトル:第2図 安定性 121℃、30分で失活、 N−塩酸と100℃、30分で安定、 N−苛性ソーダと100℃、30分で安定。
[Claims] 1. A method for producing a melanin-based substance containing protein and sugar exhibiting the following physical properties, which comprises homogenizing squid or octopus ink and dialysis of a solution obtained by removing coarse solids therefrom. . Shape: Black amorphous powder Solubility: Slightly soluble in water, insoluble in ethanol, ethyl acetate, chloroform, benzene, dimethylformamide, dimethyl sulfoxide Melting point: 300℃ or higher Elemental analysis: C47-50%, H3-4% , O38~
41%, N8-9%, ash 0.06-0.08% Molecular weight: A mixture of a substance with a molecular weight of approximately 25,000 and a substance with a molecular weight of 160,000 or more (Sephadex G-100 gel filtration) Ultraviolet absorption spectrum: Figure 2 Stability 121℃, Inactivated in 30 minutes, stable with N-hydrochloric acid at 100℃ for 30 minutes, stabilized with N-caustic soda at 100℃ for 30 minutes.
JP7743680A 1980-06-09 1980-06-09 Physiologically active substance Granted JPS574998A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP7743680A JPS574998A (en) 1980-06-09 1980-06-09 Physiologically active substance
JP63192365A JPS6463523A (en) 1980-06-09 1988-08-01 Anti-inflammatory drug

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7743680A JPS574998A (en) 1980-06-09 1980-06-09 Physiologically active substance

Publications (2)

Publication Number Publication Date
JPS574998A JPS574998A (en) 1982-01-11
JPS6410519B2 true JPS6410519B2 (en) 1989-02-22

Family

ID=13633956

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7743680A Granted JPS574998A (en) 1980-06-09 1980-06-09 Physiologically active substance

Country Status (1)

Country Link
JP (1) JPS574998A (en)

Also Published As

Publication number Publication date
JPS574998A (en) 1982-01-11

Similar Documents

Publication Publication Date Title
JP2950840B2 (en) Iron citrate-micelle complex, process for producing the same, and therapeutic agent for iron deficiency anemia
US4363801A (en) Method for treating hyperbilirubinemia
Takamine THE BLOOD-PRESSURE RAISING PRINCIPLE OF THE SUPRARENAL GLAND.
US5700832A (en) Antianemic agent containing iron and difructose
JPS6314728A (en) Preventive and remedy for hepatic disorder
JPS6410519B2 (en)
Bouissou et al. Severe idiopathic nephrotic syndrome with tubular dysfunction (report of nine pediatric cases)
US3306819A (en) Derivative of pectin, its process of preparation and its method of use
JPH0331688B2 (en)
JPH0331689B2 (en)
CN107474109A (en) 4 '-oxygen acetyl-APAK-5- hydroxyl -7- oxygen acetyl-RGDV- isoflavones, it is synthesized, activity and application
Burch et al. Lower nephron syndrome
JPS6049164B2 (en) plasma expander
JP2655592B2 (en) Process for producing very high molecular weight sulfated polysaccharides
TEPPERMAN et al. The role of hepatic detoxification in p-aminopropiophenone induced methemoglobinemia
JPH0381219A (en) Remedy for gastric mucosal disorder
CN109847067A (en) A kind of diclofenac-glycine-resveratrol conjugate, preparation method and application
Jacobson Alfalfa Saponin. Alfalfa Investigation VII.
Fantus Peroral administration of colloidal contrast medium in cholecystography
JOHN Some hitherto undescribed properties of the constituents of Witte's peptone
BE897980A (en) PROCESS FOR THE PREPARATION OF A SOLUTION FOR PHARMACEUTICAL USE CONTAINING A NEW MIXED POLYNUCLEAR IRON (III) COMPLEX AS ACTIVE INGREDIENT
WO1985003230A1 (en) Drug for phenylketonuria
JPH0288522A (en) Non-steroidal anti-inflammatory agent composition and production thereof
Hawking Pharmacology of Sulphonamides: Recent Work
Hawking Recent Work On The Pharmacology Of Sulphonamides